Commentary Open Access
Volume 1 | Issue 3 | DOI: https://doi.org/10.46439/allergy.1.014
Period-varying confirmed case-fatality risk still being depicted
Wangping Jia1,2, Ke Han1, Haibo Li3, Miao Liu1,*, Yao He1
- 1Institute of Geriatrics, Beijing Key Laboratory of Aging and Geriatrics, National clinical research center for geriatrics diseases, Second Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China
- 2Department of Military Medical Technology Support, School of Noncommissioned Officer, Army Medical University, Shijiazhuang, Hebei, China
- 3Graduate School of Peking Union Medical College, Beijing, China
Corresponding Author
Miao Liu, liumiaolmbxb@163.com
Received Date: May 22, 2020
Accepted Date: October 05, 2020
Jia W, Han K, Li H, Liu M, He Y. Period-varying confirmed case-fatality risk still being depicted. J Allergy Infect Dis 2020; 1(3):66-67.
Copyright: © 2020 Jia W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
COVID-19 vaccination in children in India: A way forward
India has an estimated population of 1.39199 billion and current vaccination approach plans to cover adult population (>18 y, about 67.53%) very soon. As on 24 December 2021, the country completed about 1.41 billion doses of COVID-19 vaccines, in about eleven months since the drive began.
COVID-19 health care worker infection: Additional concerns
Health Care worker (HCW) infection with corona virus disease 2019 (COVID-19) is a serious problem and there is a potential risk of mortality associated with it [1]. Such infection is generally attributed to transmission from patients with COVID-19 infection and there are now recommendations for best practices to limit such transmission.
COVID-19: Aspects of outpatient treatment
Coronavirus Disease 2019 (COVID-19) currently has become a significant public health crisis and one of leading causes of death internationally. A considerable number of cases progresses to pneumonia with severe respiratory failure. So far, many studies address reduction of inpatient mortality and containment of the spread of infection. Nevertheless, most infected people develop smooth symptoms and are treated ambulatory.
COVID-19 in the post-vaccination era: Who is at risk of severe disease?
Vaccination against SARS-CoV-2 began in December 2020 and with this strategy, the course of the pandemic would be modified. BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna), and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) were the main vaccines that demonstrated a reduction in hospitalization and death from SARS-CoV-2 in clinical trials. Post-vaccination infection by COVID-19 is called breakthrough infection.